SeaStar Medical Holding Corporation
ICUSeaStar Medical is a commercial-stage healthcare company developing transformational extracorporeal therapies for critically ill patients facing organ failure.
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Competitors
By market cap
By net margin
Profile
SeaStar Medical is a commercial-stage healthcare company developing transformational extracorporeal therapies for critically ill patients facing organ failure. Its core value proposition is the Selective Cytopheretic Device (SCD), a disease-modifying technology that neutralizes over-active immune cells to stop the hyperinflammation and 'cytokine storm' that leads to multi-organ failure. The company's platform is designed to integrate into existing hospital renal replacement systems to treat both acute and chronic inflammatory conditions.
SeaStar Medical holds a first-in-class position with the only FDA-approved product for pediatric AKI requiring kidney replacement therapy and holds six Breakthrough Device Designations.
Questions, answered.
- What is SeaStar Medical Holding Corporation's market cap?
- SeaStar Medical Holding Corporation (ICU) has a market capitalization of $19.6M and trades on NASDAQ.
- Who are SeaStar Medical Holding Corporation's competitors?
- SeaStar Medical Holding Corporation's key competitors include Fresenius Medical Care, ProKidney Corp. Class A Ordinary Shares, CorMedix Inc., and others. These companies compete in similar markets and product categories.
- Who does SeaStar Medical Holding Corporation partner with?
- SeaStar Medical Holding Corporation's notable partners include Fresenius Medical Care, University of Michigan, Baxter International.
- What subsidiaries does SeaStar Medical Holding Corporation have?
- SeaStar Medical Holding Corporation's subsidiaries include SeaStar Medical, Inc..
- Where is SeaStar Medical Holding Corporation headquartered?
- SeaStar Medical Holding Corporation is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2022.